Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Oculis Holding AGNASDAQ: OCS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -CHF 157.43K, compared with CHF 0 a year earlier. Trailing-twelve-month gross profit was -CHF 14.56M.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -CHF 157.43K or moves back toward the trailing-twelve-month quarterly average of -CHF 3.64M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 157.43K— QoQ
Last fiscal yearDec 2025
CHF 0+100.0% YoY
LTMMar 2026
-CHF 14.56M— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

CHF · from the income statement

Latest · FY2025
0 CHF
Year-over-year change
+100.0%

Gross Profit vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Gross profit amounts to 2889.4% of revenue for OCS, versus a peer median of 81.9%.
OCS Competitors
Gross Profit for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HROWHarrow Health, Inc.LTM Mar 2026$199.11M USD+25.5%+47.9%74.1%
OCULOcular Therapeutix, Inc.LTM Mar 2026$45.4M USD-16.1%-1.2%87.2%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$5.83M USD-88.9%-4.0%76.5%
OKYOOKYO Pharma LimitedFY2025-$2.56K USD+33.7%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M USD-4457.3%—360.9%
OCSOculis Holding AGLTM Mar 2026-CHF 14.56M CHF——2889.4%
Peer median (excluding OCS) —-16.1%-1.2%81.9%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.